# Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies

> **NCT01065025** · PHASE1 · COMPLETED · sponsor: **4SC AG** · enrollment: 60 (estimated)

## Conditions studied

- Advanced and Incurable Solid Tumors
- Malignant Lymphomas

## Interventions

- **DRUG:** 4SC-205

## Key facts

- **NCT ID:** NCT01065025
- **Lead sponsor:** 4SC AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065025, "Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01065025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*